Parexel and Datavant partner on clinical study design, operations

Doctor computer medical records
The partnership is designed to connect healthcare data from a number of real-world and clinical data sources to spur improved drug development and commercialization, the companies said. (Getty/BrianAJackson)

Parexel and Datavant, which focuses on healthcare technology, are partnering to improve the design and operations of clinical studies and the generation of real-world evidence.

The partnership is designed to connect healthcare data from a number of real-world and clinical data sources to spur improved drug development and commercialization, the companies said.

Datavant targets secure de-identification and linking of healthcare datasets.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“The exponential growth of healthcare data offers both an opportunity to incorporate this wealth of data into the clinical study processes and commercial evidence generation, and a challenge, given the disparate sources where a patient’s healthcare data may be contained,” Jason Martin, Parexel’s VP of Global Data Operations, said in a statement.

San Francisco-based Datavant’s tech allows the linking of traditional healthcare data sources like electronic medical records, claims and diagnostics with other emerging sources such as genomics, socioeconomic data, information from wearable devices and behavioral data.

Travis May, Datavant’s chief executive, said the partnership will provide “an opportunity to answer some of the most difficult questions in drug development and commercialization for the ultimate benefit of patients.”

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.